공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 비흑색종 피부암(NMSC) 시장

Non-melanoma Skin Cancer

리서치사 Global Industry Analysts, Inc.
발행일 2021년 04월 상품 코드 997519
페이지 정보 영문 175 Pages
가격
US $ 4,950 ₩ 5,625,000 PDF (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 14,850 ₩ 16,875,000 PDF (Global License to Company and its Fully-owned Subsidiaries) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 비흑색종 피부암(NMSC) 시장 Non-melanoma Skin Cancer
발행일 : 2021년 04월 페이지 정보 : 영문 175 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 비흑색종 피부암(NMSC) 시장 규모는 분석기간(2020-2027년)에 4.5%의 연평균 복합 성장률(CAGR)로 성장할 전망이며, 2020년 4억 9,980만 달러에서 2027년에는 6억 8,240만 달러에 달할 것으로 예측됩니다.

본 보고서에서 분석한 부문 중 하나인 기저세포암(BCC)은 분석기간 중 4.4%의 CAGR을 나타내고, 4억 4,250만 달러에 달할 전망입니다.

세계의 비흑색종 피부암(NMSC: Non-melanoma Skin Cancer) 시장에 대해 조사했으며, 시장 점유율, COVID-19의 영향, 동향 및 성장요인, 지역별 시장 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

조사 대상 기업 예

  • Accuray, Inc.
  • Almirall S.A.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Elekta AB
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • iCAD, Inc.
  • Ion Beam Applications SA
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Sensus Healthcare
  • Sun Pharmaceutical Industries Ltd.
  • Varian Medical Systems, Inc.

목차

I. 조사 방법

II. 개요

  • 시장 개요
    • 인플루언서 시장 인사이트
    • 세계 시장 궤적
    • 코로나19(COVID-19)의 영향과 다가오는 세계 경기침체
  • 주요 기업
  • 동향 및 성장요인
  • 세계 시장 전망

III. 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

IV. 경쟁

  • 기업 개요 : 46개사
LSH 21.04.08

Abstract:

Global Non-melanoma Skin Cancer Market to Reach $682.4 Million by 2027

Amid the COVID-19 crisis, the global market for Non-melanoma Skin Cancer estimated at US$499.8 Million in the year 2020, is projected to reach a revised size of US$682.4 Million by 2027, growing at aCAGR of 4.5% over the period 2020-2027. Basal Cell Carcinoma (BCC), one of the segments analyzed in the report, is projected to record 4.4% CAGR and reach US$442.5 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Squamous Cell Carcinoma (SCC) segment is readjusted to a revised 4.9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $147.2 Million, While China is Forecast to Grow at 4.3% CAGR

The Non-melanoma Skin Cancer market in the U.S. is estimated at US$147.2 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$120.9 Million by the year 2027 trailing a CAGR of 4.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 3.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Select Competitors (Total 46 Featured) -

  • Accuray, Inc.
  • Almirall S.A.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Elekta AB
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • iCAD, Inc.
  • Ion Beam Applications SA
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Sensus Healthcare
  • Sun Pharmaceutical Industries Ltd.
  • Varian Medical Systems, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Non-melanoma Skin Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Non-melanoma Skin Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Non-melanoma Skin Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Basal Cell Carcinoma (BCC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Basal Cell Carcinoma (BCC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Basal Cell Carcinoma (BCC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Squamous Cell Carcinoma (SCC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Squamous Cell Carcinoma (SCC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Squamous Cell Carcinoma (SCC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 16: USA Current & Future Analysis for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 17: USA Historic Review for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: USA 15-Year Perspective for Non-melanoma Skin Cancer by Segment - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) for the Years 2012, 2020 & 2027
    • TABLE 19: USA Current & Future Analysis for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 20: USA Historic Review for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: USA 15-Year Perspective for Non-melanoma Skin Cancer by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatments for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 22: Canada Current & Future Analysis for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 23: Canada Historic Review for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: Canada 15-Year Perspective for Non-melanoma Skin Cancer by Segment - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) for the Years 2012, 2020 & 2027
    • TABLE 25: Canada Current & Future Analysis for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 26: Canada Historic Review for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: Canada 15-Year Perspective for Non-melanoma Skin Cancer by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatments for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 28: Japan Current & Future Analysis for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 29: Japan Historic Review for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: Japan 15-Year Perspective for Non-melanoma Skin Cancer by Segment - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) for the Years 2012, 2020 & 2027
    • TABLE 31: Japan Current & Future Analysis for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Japan Historic Review for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: Japan 15-Year Perspective for Non-melanoma Skin Cancer by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatments for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 34: China Current & Future Analysis for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 35: China Historic Review for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: China 15-Year Perspective for Non-melanoma Skin Cancer by Segment - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) for the Years 2012, 2020 & 2027
    • TABLE 37: China Current & Future Analysis for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: China Historic Review for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: China 15-Year Perspective for Non-melanoma Skin Cancer by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatments for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 40: Europe Current & Future Analysis for Non-melanoma Skin Cancer by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 41: Europe Historic Review for Non-melanoma Skin Cancer by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: Europe 15-Year Perspective for Non-melanoma Skin Cancer by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 43: Europe Current & Future Analysis for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Europe Historic Review for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: Europe 15-Year Perspective for Non-melanoma Skin Cancer by Segment - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) for the Years 2012, 2020 & 2027
    • TABLE 46: Europe Current & Future Analysis for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Europe Historic Review for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: Europe 15-Year Perspective for Non-melanoma Skin Cancer by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatments for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 49: France Current & Future Analysis for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: France Historic Review for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: France 15-Year Perspective for Non-melanoma Skin Cancer by Segment - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) for the Years 2012, 2020 & 2027
    • TABLE 52: France Current & Future Analysis for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: France Historic Review for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: France 15-Year Perspective for Non-melanoma Skin Cancer by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatments for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 55: Germany Current & Future Analysis for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Germany Historic Review for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: Germany 15-Year Perspective for Non-melanoma Skin Cancer by Segment - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) for the Years 2012, 2020 & 2027
    • TABLE 58: Germany Current & Future Analysis for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Germany Historic Review for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: Germany 15-Year Perspective for Non-melanoma Skin Cancer by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatments for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 61: Italy Current & Future Analysis for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Italy Historic Review for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: Italy 15-Year Perspective for Non-melanoma Skin Cancer by Segment - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) for the Years 2012, 2020 & 2027
    • TABLE 64: Italy Current & Future Analysis for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Italy Historic Review for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: Italy 15-Year Perspective for Non-melanoma Skin Cancer by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatments for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 67: UK Current & Future Analysis for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: UK Historic Review for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: UK 15-Year Perspective for Non-melanoma Skin Cancer by Segment - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) for the Years 2012, 2020 & 2027
    • TABLE 70: UK Current & Future Analysis for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 71: UK Historic Review for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: UK 15-Year Perspective for Non-melanoma Skin Cancer by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatments for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 73: Rest of Europe Current & Future Analysis for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Rest of Europe Historic Review for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: Rest of Europe 15-Year Perspective for Non-melanoma Skin Cancer by Segment - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) for the Years 2012, 2020 & 2027
    • TABLE 76: Rest of Europe Current & Future Analysis for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Rest of Europe Historic Review for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: Rest of Europe 15-Year Perspective for Non-melanoma Skin Cancer by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatments for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 79: Asia-Pacific Current & Future Analysis for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Asia-Pacific Historic Review for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: Asia-Pacific 15-Year Perspective for Non-melanoma Skin Cancer by Segment - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) for the Years 2012, 2020 & 2027
    • TABLE 82: Asia-Pacific Current & Future Analysis for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Asia-Pacific Historic Review for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: Asia-Pacific 15-Year Perspective for Non-melanoma Skin Cancer by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatments for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 85: Rest of World Current & Future Analysis for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Rest of World Historic Review for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: Rest of World 15-Year Perspective for Non-melanoma Skin Cancer by Segment - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) for the Years 2012, 2020 & 2027
    • TABLE 88: Rest of World Current & Future Analysis for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Rest of World Historic Review for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: Rest of World 15-Year Perspective for Non-melanoma Skin Cancer by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatments for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 46
Back to Top
전화 문의
F A Q